CNR Institutional Research Information System

FONTI, ROSA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.705
NA - Nord America 918
EU - Europa 399
SA - Sud America 237
AF - Africa 25
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 3.288
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 852
SG - Singapore 653
CN - Cina 388
HK - Hong Kong 245
BR - Brasile 190
VN - Vietnam 142
IT - Italia 112
BD - Bangladesh 94
FR - Francia 94
NL - Olanda 82
KR - Corea 67
JP - Giappone 40
DE - Germania 29
CA - Canada 28
GB - Regno Unito 21
FI - Finlandia 19
IN - India 18
MX - Messico 16
EC - Ecuador 13
AR - Argentina 12
ZA - Sudafrica 11
IQ - Iraq 9
CO - Colombia 8
ID - Indonesia 8
IL - Israele 7
CL - Cile 5
UA - Ucraina 5
AZ - Azerbaigian 4
ES - Italia 4
IE - Irlanda 4
RU - Federazione Russa 4
TR - Turchia 4
TT - Trinidad e Tobago 4
AT - Austria 3
DO - Repubblica Dominicana 3
EG - Egitto 3
JM - Giamaica 3
KH - Cambogia 3
KZ - Kazakistan 3
MA - Marocco 3
PK - Pakistan 3
PL - Polonia 3
PT - Portogallo 3
PY - Paraguay 3
SA - Arabia Saudita 3
SE - Svezia 3
SV - El Salvador 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
CR - Costa Rica 2
DZ - Algeria 2
LA - Repubblica Popolare Democratica del Laos 2
LT - Lituania 2
MD - Moldavia 2
PE - Perù 2
PH - Filippine 2
TH - Thailandia 2
TN - Tunisia 2
TW - Taiwan 2
UZ - Uzbekistan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
BB - Barbados 1
BG - Bulgaria 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
GA - Gabon 1
GP - Guadalupe 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
IM - Isola di Man 1
IS - Islanda 1
JO - Giordania 1
LC - Santa Lucia 1
LV - Lettonia 1
NP - Nepal 1
PA - Panama 1
RO - Romania 1
RS - Serbia 1
SN - Senegal 1
UY - Uruguay 1
Totale 3.288
Salva come PNG Salva come JPEG
Città #
Singapore 404
Santa Clara 314
Hong Kong 243
Hefei 130
Beijing 100
San Jose 87
Ashburn 77
Lauterbourg 72
Seoul 67
Ho Chi Minh City 56
Los Angeles 44
Hanoi 36
Tokyo 29
New York 19
Naples 14
Milan 12
São Paulo 12
Dallas 11
Düsseldorf 11
Helsinki 11
Buffalo 9
Orem 9
Minamishinagawa 8
Chicago 7
Frankfurt am Main 7
Mexico City 7
Rio de Janeiro 7
Rome 7
Atlanta 6
Belleville 6
Casandrino 6
Haiphong 6
Johannesburg 6
Suzhou 6
Bauru 5
Bengaluru 5
Brooklyn 5
Guarulhos 5
Guayaquil 5
Hangzhou 5
Quito 5
Toronto 5
Baku 4
Biên Hòa 4
Charlotte 4
Da Nang 4
Dublin 4
Guangzhou 4
Lappeenranta 4
Montreal 4
Poplar 4
Shanghai 4
Wingate 4
Abaetetuba 3
Baghdad 3
Belo Horizonte 3
Benito Juarez 3
Bologna 3
Buenos Aires 3
Carapicuíba 3
Chongqing 3
Columbus 3
Dhaka 3
Ha Long 3
Joinville 3
Jundiaí 3
Manchester 3
Palermo 3
Paris 3
Phnom Penh 3
Phoenix 3
Porto Alegre 3
Rio Grande 3
San Antonio 3
San Salvador 3
Shenzhen 3
Springfield 3
Stockholm 3
São Gonçalo 3
São Luís 3
Turku 3
Zhenjiang 3
Acalanes Ridge 2
Almaty 2
Augusta 2
Avon Park 2
Barra Mansa 2
Blumenau 2
Boardman 2
Boca da Mata 2
Chestertown 2
Cleveland 2
Coeur d'Alene 2
Council Bluffs 2
Erbil 2
Falkenstein 2
Florence 2
Fortaleza 2
Franca 2
Gaffney 2
Totale 2.053
Salva come PNG Salva come JPEG
Nome #
18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma 94
Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer 92
Monitoring Reversal of Concurrent Mechanisms of Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by 18F-FLT PET/CT 90
Changes of Glycolytic Pathway in Response to Efficient Inhibition of EGFR Signaling in Non-small Cell Lung Cancer (NSCLC) 87
Early reduction of 18F-FDG uptake in non-small lung cancer treated with EGFR tyrosine kinase inhibitors reflects reversal of Warburg effect and reactivation of oxidative phosphorylation. 87
The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study 82
Metabolic Tumor Volume assessed by 18F-FDG-PET/CT in the evaluation of plasma cell mass and prediction of outcome in patients with multiple myeloma 71
Molecular mechanisms of decreased aerobic glycolysis in non-small lung cancer treated with EGFR tyrosine kinase inhibitors. European Society for Molecular Imaging Meeting 70
Prognostic role of 18F-FDG PET/CT in the postoperative evaluation of differentiated thyroid cancer patients 69
Bone Scintigraphy and SPECT/CT in Bisphosphonate-Induced Osteonecrosis of the Jaw 67
Gefitinib, a selective, tyrosine kinase inhibitor increases 99mTc-MIBI uptake in Bcl-2 overexpressing breast cancer cells. 65
Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by F-18-fluorothymidine 65
18F-FLT PET/CT for Detection of Functional Cross-talk between MET and EGFR in Non-small Cell Lung Cancer Resistant to EGFR Inhibitors 65
Non-invasive detection of epithelial mesenchymal transition phenotype and metastatic dissemination of lung cancer by liquid biopsy 62
18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction of Outcome of Patients With Multiple Myeloma: A Comparative Study 58
99mTc-sestamibi scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients. 57
Imaging integrato del Mieloma Multiplo con 18FDG-PET/TC, TC99M-MIBI e RM 55
Bone Marrow uptake of 99mTc-MIBI in patients with multiple myeloma 55
A reversible shift of driver dependence from egfr to notch1 in non-small cell lung cancer as a cause of resistance to tyrosine kinase inhibitors 55
Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy 55
Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma 53
Heterogeneity of SSTR2 Expression Assessed by 68Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors 53
Preclinical imaging for targeting cancer immune evasion 52
Non-Canonical Role of PDK1 as a Negative Regulator of Apoptosis through Macromolecular Complexes Assembly at the ER–Mitochondria Interface in Oncogene-Driven NSCLC 52
Preclinical Imaging in Targeted Cancer Therapies 45
Coordinate modulation of glycolytic enzymes and OXPHOS by imatinib in BCR-ABL driven chronic myelogenous leukemia cells 44
Neutrophil Extracellular Traps as an Adhesion Substrate for Different Tumor Cells Expressing RGD-Binding Integrins 44
IS 2-DEOXY-2-[18F]FLUORO-D-GLUCOSE PET/CT ACQUISITION FROM THE UPPER THIGH TO THE VERTEX OF SKULL USEFUL IN ONCOLOGICAL PATIENTS? 43
Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer 43
Dynamic coupling of 99mtc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients 42
Detection of Leptomeningeal Involvement by 18F-FDG-PET/CT in a Patient With Non-Hodgkin Lymphoma 41
PET/CT in cancer research: from preclinical to clinical applications 40
99mTc-MIBI in the evaluation of breast cancer biology 40
Combined 18F-FDG-PET/CT and 111In-Octreotide SPECT for Evaluation of Thymic Epithelial Tumors 39
Evidence of Brown Adipose Tissue Astivity assessed by 18F-FDG-PET/CT in Females with Constitutional Leanness. 37
Functional imaging of multidrug resistance in breast cancer 37
Metastasis to the Sellar/Suprasellar Region in a Patient With Endometrial Carcinoma Detected by F-18-FDG PET/CT 36
Sentinel lymph node identification in breast cancer patients. 36
Imaging of immunotherapy response in non-small cell lung cancer: challenges and perspectives 36
Metabolic Tumor Volume Assessed by 18F-FDG PET/CT for the Prediction of Outcome in Patients with Multiple Myeloma 36
18F-FLT PET/CT as a surrogate biomarker for synergy quantification in EGFR targeted combination therapy of NSCLC 36
Early F-18-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors 35
18F-FDG-PET/CT and 111In-Octreotide SPECT in the Evaluation of Patients with Neuroendocrine Lung Tumors 35
Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis. 35
PET/CT in radiation oncology 35
Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma 35
Tumor Detection in Syndromic NET: Zollinger-Ellison Syndrome. 35
Washout of 99mTc-Sestamibi in predicting response to chemoterapy in patients with multiple myeloma 34
Evaluation of metabolic response with F-18-FDG PET-CT in patients with advanced or recurrent thymic epithelial tumors 34
Molecular imaging of drug resistance in cancer 34
Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma 33
99mTc-MIBI in the evaluation of breast cancer biology 33
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET 33
New frontiers of nuclear medicine. 33
Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma 32
Combined Imaging With F-18-FDG-PET/CT and In-111-Labeled Octreotide SPECT for Evaluation of Thymic Epithelial Tumors 32
Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography 31
18F-FDG-PET/CT, 99mTc-MIBI and MRI in the Prediction of Outcome of Patients with Multiple Myeloma 31
Nuclear imaging in cancer theranostics 30
Lymph node mapping and sentinel lymph node biopsy for evaluation of axillary lymph node status in early invasive breast cancer 29
Stato dell'arte dell'imaging preclinico in oncologia 29
18F-FDG-PET/CT and 111In-Octreotide SPECT in Patients with Metastatic Medullary Thyroid Carcinoma 28
18F-FLT PET/CTas a surrogate biomarker for synergy quantification in EGFR targeted combination therapy of NSCLC 28
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-X-L modulation of inositol trisphosphate receptor type 3 27
. A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in patients with progressive medullary thyroid cancer (MTC) and the combination with RAD001 upon progression 27
Follow-up of solitary plasmacytoma by 99mTc-sestamibi scintigraphy 27
Oncologia. In "Medicina Nucleare. Metodologie ed Applicazioni Diagnostiche". 26
Bone Scintigraphy and SPECT/CT in Bisphosphonate-Induced Osteonecrosis of the Jaw 26
Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer 24
Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma. 24
Role of 68Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1) 23
PET/CT in cancer research: from preclinical to clinical applications 23
Evidence of brown fat activity in constitutional leanness 23
Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer 22
Bone Marrow uptake of 99mTc-MIBI in patients with multiple myeloma - Reply 19
A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in patients with progressive medullary thyroid cancer (MTC): preliminary data. 19
Totale 3.310
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.845
article - articoli 9.802
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 479
Totale 21.126
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202423 0 0 0 0 0 0 0 0 1 7 10 5
2024/20251.213 8 13 88 58 321 30 16 37 39 117 259 227
2025/20261.995 96 163 157 236 436 94 280 68 112 116 113 124
2026/202779 79 0 0 0 0 0 0 0 0 0 0 0
Totale 3.310